The challenge of undiagnosed pre-diabetes, diabetes and associated cardiovascular disease

International Journal of Diabetes Mellitus

Volumn 2, Issue 1, 2010, Pages 43-46

  Gossain, Ved V ^a   Aldasouqi, Saleh ^a  

^a MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

Cardiovascular disease; Diabetes; HbA1c; Pre diabetes; Undiagnosed diabetes

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C;

CARDIOVASCULAR DISEASE; DIAGNOSTIC ERROR; DIAGNOSTIC TEST; DISEASE ASSOCIATION; DISEASE COURSE; GLUCOSE BLOOD LEVEL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PREGNANCY DIABETES MELLITUS; PRIORITY JOURNAL; PUBLIC HEALTH PROBLEM; REVIEW; SCREENING TEST; VASCULAR DISEASE;

EID: 77749310076     PISSN: 18775934     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijdm.2009.10.004     Document Type: Review

References (60)

1. The American Diabetes Association. [accessed 12.08.08].
2. Cowie C.C., Rust K.F., Ford E.S., Eberthardt M.S., Byrd-Holt D.D., Li C., et al. Full accounting of diabetes and pre-diabetes in the US population in 1988-1994 and 2005-2006. Diab Care 32 2 (2009) 287-294
3. Pierce M.B., Zaniotto P., Steel N., and Mindell J. Undiagnosed diabetes - data from English longitudinal study of ageing. Diab Med 26 (2009) 625-679
4. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diab Care 2004;27(5):1047-53.
5. IDF - Diabetes Atlas: Prevalence - http://www.eatlas.idf.org/indexcc67.html; 2009.
6. Unwin N., Shaw J., Zimmet P., and Alberti K.G.M.M. Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. Diabet Med 19 (2002) 708-723
7. Gillies C.L., Abrams K.R., Lambert P.C., Cooper N.J., Sutton A.J., Hsu R.T., et al. Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance. Systematic review and meta-analysis. BMJ 334 7588 (2007) 299-307
8. Zhiheng H., and King G.L. Microvascular complications of diabetes. Endocrinol Metab Clin North Am 33 (2004) 215-238
9. Kannel W.B., and McGee D.L. Diabetes and cardiovascular risk factors: the Framingham study. Circulation 59 1 (1979) 8-13
10. Harris M.I., and Entmacher P.S. Mortality from diabetes. In: Harris M.I., and Hamman R. (Eds). Diabetes in America (1985), US Government Printing Office, Washington, DC 1-48 [Publication #85-1468]
11. Aldasouqi S.A., Gossain V.V., and Little R.R. Undiagnosed diabetes equals undiagnosed CVD: a call for more effective diabetes screening. Rev Endocrinol 3 (2009) 21-23
12. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979;28:1039-57.
13. The expert committee on the diagnosis and classification of diabetes mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diab Care 1997;20(7):1183-97.
14. The expert committee on the diagnosis and classification of diabetes mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diab Care 2003;26(11):3160-67.
15. ACE/AACE consensus statement. Diagnosis and management of pre-diabetes in the continuum of hyperglycemia. Endo Pract 2008;14:933-46.
16. Alberti K.G.M.M., Zimmet P., and Shaw J. International diabetes federation: a consensus on type 2 diabetes prevention. Diab Med 24 (2007) 451-463
17. Shaw J.E., Zimmet P.Z., De Courten M., Dowse G.K., Chitson P., Gareeboo H., et al. Impaired fasting glucose or impaired glucose tolerance. What best predicts future diabetes in Mauritius?. Diab Care 22 (1999) 399-402
18. Tominaga M., Eguchi H., Manaka H., Igarashi K., Kato T., and Sekikawa A. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. Diab Care 22 (1999) 920-924
19. Wong T.Y., Liew G., Tapp R.J., et al. Relation between fasting glucose and retinopathy for diagnosis of diabetes: three population based cross sectional studies. Lancet 371 (2008) 736-743 [erratum in Lancet 2008;371:1838]
20. a (2003) 6s-11S
21. Levitzky Y.S., Pencina M.J., D'Agostino R.B., Meigs J.M., Vasan R.S., et al. Impact of impaired fasting glucose on cardiovascular disease: the Framingham heart study. J Am Coll Cardiol 22 (2008) 264-270
22. Fuller J.H., Shipley M.J., Rose G., Jarrett R.J., and Keen H. Coronary-heart-disease risk and impaired glucose tolerance. The Whitehall study. Lancet 1 (1980) 1373-1376
23. Lowe L.P., Liu K., Greenland P., Metzger B.E., Dyer A.R., and Stamler J. Diabetes, asymptomatic hyperglycemia, and 22-year mortality in black and white men: the Chicago heart association detection project in industry study. Diab Care 20 (1997) 163-169
24. DECODE study group. The European diabetes epidemiology group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Int Med 2001;161:397-404.
25. Nathan D.M. Long-term complications of diabetes mellitus. NEJM 328 (1993) 1676-1685
26. Kannel W.B., and McGee D.L. Diabetes and cardiovascular disease. The Framingham study. JAMA 241 (1979) 2035-2038
27. Khaw K.T., Warcham N., Bingham S., Luben R., Welch A., and Day N. Association of HbA1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk. Ann Int Med 141 (2004) 413-420
28. Danaei G., Lawes C.M.M., Vander Hoorn S., Murray C.J.L., and Ezzati M. Global and regional mortality from ischaemic heart disease and stroke attributable to higher-than-optimum blood glucose concentration: comparative risk assessment. Lancet 368 (2006) 1651-1659
29. Saydah S., Imperatore G., Tao M., and Gregg E. GHb level and subsequent mortality among adults in the US. Diab Care 32 (2009) 1440-1446
30. Dale A.C., Midthjell K., Nilsen T.I., Wiseth R., and Vatten L.J. Glycaemic control in newly diagnosed diabetes patients and mortality from ischaemic heart disease: 20-year follow-up of the HUNT study in Norway. Eur Heart J 30 (2009) 1372-1377
31. DCCT. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. NEJM 1993;329:977-86.
32. UK prospective diabetes study [UKPDS] group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes [UKPDS 33]. Lancet 1998;352:837-53.
33. Stratton I.M., Adler A.I., Neil H.A.W., Matthews D.R., Manley S.E., Cull C.A., et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321 (2000) 405-412
34. Holman R.R., Paul S.K., Bethel M.A., Matthews D.R., and Neil A.W. 10-year follow-up of intensive glucose control in type 2 diabetes. NEJM 359 (2008) 1577-1589
35. American diabetes association. Clinical practice recommendations 2009. Diab Care 2009;32(Suppl. 1):s1-94.
36. Nathan D.M. Glycemic management of type 2 diabetes. Arch Intern Med 168 (2008) 2064-2066
37. The action to control cardiovascular risk in diabetes study group. Effects of intensive glucose lowering in type 2 diabetes. NEJM 2008;358:2545-59.
38. The ADVANCE collaborative group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. NEJM 2008;358:2560-72.
39. Goede P., Lund-Andersen H., Parving H.H., and Pederson O. Effect of a multifactorial intervention on mortality in type 2 diabetes. New Eng J Med 358 (2008) 580-591
40. US preventive services task force. Screening for type 2 diabetes mellitus in adults: US preventive services task force recommendation statement. Annals of Int Med 2008;148:846-55.
41. Waugh N., Scotland G., McNamee P., Gillett M., Brennan A., Goyder E., et al. Screening for type 2 diabetes: literature review and economic modeling. Health Technol Assess 11 (2007) 1-125
42. Sheehy A.M., Coursin D.B., and Gabbay R.A. Back to Wilson and Jungner: 10 good reasons to screen for type 2 diabetes mellitus. Mayo Clin Proc 84 (2009) 38-42
43. Lawler F.H. Reasons to exercise caution when considering a screening program for type 2 diabetes mellitus. Mayo Clin Proc 84 (2009) 34-36
44. Aldasouqi S.A., and Gossain V.V. Revisiting screening for type 2 diabetes mellitus: to screen or not to screen, that is the question. Mayo Clin Proc (2009)
45. Perry R.C., Shankar R.R., Finberg N., McGill J., and Baron A.D. HbA1c measurements improves the detection of type 2 diabetes in high-risk individuals with nondiagnostic levels of fasting plasma glucose: the early diabetes intervention program [EDIP]. Diab Care 24 (2001) 465-471
46. Bennett C.M., Guo M., and Dharmage S.C. HbA1c as a screening tool for detection of type 2 diabetes: a systematic review. Diab Med 24 (2007) 333-343
47. Aldasouqi S.A., and Gossain V.V. HbA1c: past, present and future. Ann Saudi Med 28 (2008) 411-419
48. Aldasouqi S.A., Solomon D., Bokhari S.A., Khan P.M., Muneera S., and Gossain V.V. Glycohemoglobin A1c: A promising screening tool in gestational diabetes mellitus. Int J Diab Dev Ctries 28 4 (2008) 121-124
49. McCane D.R., Hanson R.L., Charles M.A., Jacobsson L.T.H., Pettit D., Bennett P.H., et al. Comparison of tests for gyrated haemoglobin and fasting and two hour plasma glucose concentrations as diagnostic methods for diabetes. BMJ 308 (1994) 1323-1328
50. Saudek C.D., Herman W.H., Saeks D.B., Bergenstal R.M., Edelman D., and Davidson M.B. A new look at screening and diagnosing diabetes mellitus. J Clin Endocrinol Metab 93 (2008) 2447-2453
51. American diabetic association. Professional section quarterly. Winter 2009. p. 1.
52. Fachnie J.D., Whitehouse F.W., and McGrath Z. Vomiting during OGTT in third trimester of pregnancy. Diab Care 11 (1988) 818
53. Artal R., Mosley G.M., and Doney F.J. Glycohemoglobin as a screening test for gestational diabetes. Am J Obstet Gynecol 148 (1984) 412-414
54. Morris M.A., Grandis A.S., and Litton J. Glycosylated hemoglobin a sensitive indicator of gestational diabetes. Obstet Gynecol 68 (1986) 357-361
55. Shah B.D., Cohen A.W., May C., and Gabbe S.G. Comparison of glycohemoglobin determination and one hour glucose screen in identification of gestational diabetes. Am J Obstet Gynecol 144 (1982) 774-777
56. McFarland K.F., Murtiashaw M., and Baynes J.W. Clinical value of glycosylated serum proteins and glycosylated hemoglobin levels in the diagnoses of gestational diabetes mellitus. Obstet Gynecol 64 (1984) 516-518
57. Cocilovo G., Guerra S., Coka F., and Tomasi F. Glycosylated hemoglobin [HbA1] assay as a test for detection and surveillance of gestational diabetes. A reappraisal. Diab Metab 13 (1987) 426-430
58. Agarwal M.M., Hughes P.F., Punnose J., Ezimokhai M., and Thomas L. Gestational diabetes screening of a multiethnic, high-risk population using glycated proteins. Diab Res Clin Pract 51 (2001) 67-73
59. Agarwal M.M., Dhatt G., Punnose J., and Koster G. Gestational diabetes: a reappraisal of HbA1c as a screening test. Acta Obstet Gynecol Scan 84 (2005) 1159-1163
60. Simmons D., Rowan J., Reid R., and Campbell N. On behalf of national GDM working party. Screening, diagnosis and services for women with gestational diabetes mellitus [GDM] in New Zealand: a technical report from the national GDM technical working party. New Zealand Med J 121 (2008) 74-85